| Abstract: |
Leukemia is well suited for monoclonal antibody therapy due to the accessible, differentiation antigens that characterize stages of maturation. In this paper, we describe the use of radio-labeled M195, a murine IgG2a, anti-CD33 monoclonal antibody, that can be used to effectively cytoreduce AML cells in relapsed patients when tumor burden is high; or to eliminate minimal residual disease and lengthen disease-free survival in patients with APL in remission. To decrease the likelihood of immunogenicity, a humanized IgG1 version of M195 was constructed that demonstrated a higher avidity and improved effector function than the parent murine antibody. Preliminary results of the first trial in AML using a humanized antibody showed specific bone marrow targeting without an immunogenic response. © 1993 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted. |
| Keywords: |
cancer survival; clinical article; human cell; clinical trial; conference paper; binding affinity; animal; mice; bone marrow; cell maturation; monoclonal antibody; cancer regression; antibodies, monoclonal; immunoglobulin g; isotope labeling; iodine radioisotopes; immunogenicity; effector cell; target cell; phase 1 clinical trial; antigens, cd; radioimmunotherapy; clinical trials; intravenous drug administration; antigens, differentiation, myelomonocytic; acute myelogenous leukemia; myeloid leukemia; turnover time; m195; lymphocyte antigen; leukemia, myelocytic, acute; humanized antibody; cd33; human; priority journal; radiolabel
|
